|
|||||
|
|
Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions |
|
| Affiliation: | 1. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;2. Center for Public Health Initiatives, University of Pennsylvania, Philadelphia, PA, USA |
| Abstract: | |
| Keywords: | access cardiovascular disease health policy PCSK9 inhibitors prior authorization specialty drugs |
| 本文献已被 ScienceDirect 等数据库收录！ | |